E-Newsletter - July 2022
Recently Activated Trials


Two alliance trials now actively Enrolling participants
with BREAST CANCER, RESECTED MUCOSAL MELANOMA
 

Alliance A221803: Mepitel film for the reduction of radiation dermatitis in breast cancer patients undergoing post-mastectomy radiation therapy: A randomized phase III clinical trial

Overview: This phase III trial studies how well Mepitel Film works in reducing radiation dermatitis (redness and peeling) in patients with breast cancer during radiation therapy after a mastectomy. Mepitel Film may reduce the severity of skin redness and peeling in the area of radiation.

Study Chair: Kimberly Corbin, MD, Mayo Clinic | Activated: 6/15/2022 | CT.gov Link: https://bit.ly/Alliance-A221803 | Alliance Member Site
 

Alliance A091903: A randomized phase II trial of adjuvant nivolumab with or without cabozantinib in patients with resected mucosal melanoma

Overview: This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving nivolumab in combination with cabozantinib could prevent cancer from returning.

Study Chair: Alexander Shoushtari, MD, Memorial Sloan Kettering Cancer Center | Activated: 6/1/2022 | CT.gov Link: https://bit.ly/Alliance-A091903 | Alliance Member Site

 

 

For other articles in this issue of the Alliance E-news Newsletter, see below: